Add to ORKG<em>Okavax is the first vaccine (based on strain Oka) against varicella in the world. It has high immunogenicity, provides maximally prolonged defence due to forming of cell immunity. Thus, Okavax is efficient against severe varicella. Efficiency of this vaccine is confirmed with results of studies during 20 years. Okavax has good tolerability; it can be recommended to all patients after 12 months old, especially to patients from risk groups. </em><br /><strong><em>Key words: children, varicella, vaccination.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em><em>Voprosy sovremennoi pediatrii — </em></em></em>Current Pediatrics. 2010;9(5):99-102)</em></span
peer reviewedThe seriousness of varicella-zoster virus (VZV) infection as a public health issue is b...
Healthy, unimmunized children who have not had varicella infection should be vaccinated (strength of...
Background: Varicella infection can be a severe disease, especially in immunosuppressed patients. He...
<em>Varicella is a disease which can be stopped by methods of specific prophylaxis. At the same time...
Currently varicella is incorporated into the immunizations schedules in many European countries. How...
The article focuses on immunological prevention of varicella, particularly efficacy and advisability...
Background. Exposure of immunocompromised children to varicella often requires postexposure prophyla...
National varicella immunization coverage using the current 1-dose immunization strategy has increase...
Varicella zoster virus causes an acute infection that affects most children globally, but the age of...
An Oka strain varicella vaccine developed by SmithKline Beecham Biologicals in the early 1980s is re...
Varicella — is a common viral infection that can cause complications and adverse outcome not only in...
Varicella is an infectious disease caused by a virus of the herpes virus family (VZV) affecting pred...
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and ...
tion with two doses of Varivax was introduced in the childhood immunisation schedule for children ag...
Aim: Varicella is predominantly a childhood disease in non-vaccinated populations. The purpose of th...
peer reviewedThe seriousness of varicella-zoster virus (VZV) infection as a public health issue is b...
Healthy, unimmunized children who have not had varicella infection should be vaccinated (strength of...
Background: Varicella infection can be a severe disease, especially in immunosuppressed patients. He...
<em>Varicella is a disease which can be stopped by methods of specific prophylaxis. At the same time...
Currently varicella is incorporated into the immunizations schedules in many European countries. How...
The article focuses on immunological prevention of varicella, particularly efficacy and advisability...
Background. Exposure of immunocompromised children to varicella often requires postexposure prophyla...
National varicella immunization coverage using the current 1-dose immunization strategy has increase...
Varicella zoster virus causes an acute infection that affects most children globally, but the age of...
An Oka strain varicella vaccine developed by SmithKline Beecham Biologicals in the early 1980s is re...
Varicella — is a common viral infection that can cause complications and adverse outcome not only in...
Varicella is an infectious disease caused by a virus of the herpes virus family (VZV) affecting pred...
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and ...
tion with two doses of Varivax was introduced in the childhood immunisation schedule for children ag...
Aim: Varicella is predominantly a childhood disease in non-vaccinated populations. The purpose of th...
peer reviewedThe seriousness of varicella-zoster virus (VZV) infection as a public health issue is b...
Healthy, unimmunized children who have not had varicella infection should be vaccinated (strength of...
Background: Varicella infection can be a severe disease, especially in immunosuppressed patients. He...